Kornimate/medical-research-clean huggingface dataset:
hand training device for cognitive care

Conditions: Healthy Elderly; Mild Cognitive Impairment (MCI)

Summary: previous studies indicated that auditory stimulation as an external cue might have positive impacts on sensorimotor synchronization. additionally, according to previous reports apart from traditional interventions, digitized game-based device, such as ftombvg, are beneficial for the brain activation in elderly. moreover, enhanced finger force control and coordination lead to better hand dexterity and is believed to eventually improve life independence in the healthy elderly and the elderly with cognitive decline. therefore, this study aims to develop an advanced systems based on the previous one, that can provide hand function rehabilitation, cognitive training, and emotional comfort for the elderly or people suffer from cognitive deficiency. they can enhance their finger force control or visual to motor synchronization by music embedded during the gaming process.


Eligibility criteria:
inclusion criteria: * ability to communicate in mandarin chinese or taiwanese * mci, according to clinical neurological assessment, montreal cognitive assessment (moca):≦25\&≧19 * ability to perform adl independently, no hand function disability * voluntarily participation and ability to sign the informed consent form exclusion criteria: * alzheimers disease diagnosed by physicians or meeting the diagnostic criteria for dementia * physician's diagnosis of stroke * any mental illness or behavior problems and inability to cooperate with the trainer * visual impairment or hand diseases resulting in an inability to perform finger press * received other cognitive or physical training in the past year * any sight, hearing, or communication impairment

Keywords: functional near infrared spectroscopy parameters of digit force independence pressing evaluation and training system
magnesium sulfate for the improvement of cognition in patients with alzheimer disease

Conditions: Alzheimer Disease

Summary: this study is to examine the possible effect of supplementing magnesium sulfate on patients with alzheimer disease (ad) in controlling or reducing the amount of amyloid present in the brain, and increasing cognitive ability in individuals that have amyloid deposits.

recent findings suggest magnesium may be effective in ameliorating symptoms in an alzheimer's disease-like pathological progression by reducing aβ-plaque, thus preventing synapse loss and memory decline in transgenic mice. common forms include magnesium sulfate. as a nutritional adjunct in hyperalimentation, the precise mechanism of action for magnesium is uncertain. predominant deficiency effects are neurological, e.g., muscle irritability, clonic twitching and tremors. hypocalcemia and hypokalemia often follow low serum levels of magnesium. while there are large stores of magnesium present intracellularly and in the bones of adults, these stores often are not mobilized sufficiently to maintain plasma levels. parenteral magnesium therapy repairs the plasma deficit and causes deficiency symptoms and signs to cease. to provide a comprehensive clinical evaluation of the effects of magnesium sulfate in ad patients, this study is designed to assess the impact of magnesium sulfate on amyloid plaque to generate valuable data on clinical utility for the use of diagnostic algorithms and foundation for the development of possible treatment.

Eligibility criteria:
inclusion criteria: * outpatients with a diagnosis of alzheimer's disease. * exhibiting an onset and progression of cognitive dysfunction during at least 3 months prior to the screening period. * subject or representative is willing to sign the consent for prior to enrollment into the study and to participate in all aspects of the study. prospective subject must give verbal assent if unable to sign written consent. exclusion criteria: * patients with neurodegenerative diseases other than alzheimer's disease. * patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc. * patients with clinically significant cardiovascular disease. * patients with history of clinically-evident stroke. * patients with history of cancer in the last 5 years. * patients with clinically-significant systemic illness that may affect safety or completion of the study. * currently taking any medications that are known to interact with magnesium. * currently taking antibiotics as the study product may reduce the absorption of antibiotics. a washout period of 2 weeks is allowed.
factors associated with failure of hfno in covid-19 icu patients

Conditions: COVID-19 Pneumonia

Summary: to determine the factors associated with ohd failure in covid-19 patients admitted to an intensive care unit

patients admitted into 1 participating icu for acute hypoxemic respiratory failure due to covid-19 between 02/01/2020 and 06/01/2022 will be assessed for ohd failure

Eligibility criteria:
inclusion criteria: * patients admitted in icu for covid-19 pneumonia exclusion criteria: * under immediate ecmo * secondary transferred from another icu * readmission in the icu * initial limitation of care
trabectedin and irinotecan for refractory pediatric sarcomas

Conditions: Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Rhabdomyosarcoma

Summary: the purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.


Eligibility criteria:
inclusion criteria: * adolescents and young adults (age10 - 40 yoa) with refractory sarcoma, for which there are presently no further treatment options in euro-ewing/ euramos/cws (i.e. ≥ second relapse in es, resistance to surgery in osteosarcoma, relapsed rhabdomyosarcoma) and have been treated with a combined chemotherapy of trabectedin and irinotecan (described in intervention) * existing matched control in existing study databases * have started of treatment within three months of last progress key exclusion criteria: * patients newly diagnosed or in first relapse.

Keywords: pediatric sarcomas ewing sarcoma rhabdomyosarcoma soft tissue sarcoma
a study to investigate the safety and efficacy of zs in patients with hyperkalemia

Conditions: Hyperkalemia

Summary: to evaluate the efficacy of two different doses (5 and 10 g) of zs orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial zs therapy (10g tid).


Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * female and male patients aged ≥18 and ≤ 90 years * two consecutive i-stat potassium values, measured 60-minutes (± 10 minutes) apart, both ≥ 5.1 mmol/l and measured within 1 day of the first zs dose on 48-hour open-label initial phase day 1 * ability to have repeated blood draws or effective venous catheterization * female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study and for 3 months after the last dose of zs/matching placebo to prevent pregnancy. exclusion criteria: * involvement in the planning and/or conduct of the study * participation in another clinical study with an investigational product during the last 3 months * pseudohyperkalemia signs and symptoms * patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug * patients treated with resins,calcium acetate,calcium carbonate, or lanthanum carbonate,within 7 days prior to the first dose of study drug * patients with a life expectancy of less than 3 months * patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol * female patients who are pregnant, lactating, or planning to become pregnant * patients with diabetic ketoacidosis * presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated * known hypersensitivity or previous anaphylaxis to zs or to components thereof * patients with cardiac arrhythmias that require immediate treatment * patients on dialysis * patients who are blood donors should not donate blood during the study and for 3 months following their last dose of zs
voices socials for older veterans with depression

Conditions: Depression; Loneliness; Isolation

Summary: voices veterans socials (vs) support veterans in the community through weekly social groups. veterans socials have the potential to improve social functioning, mental health symptoms, and create lasting social support. this project aims to evaluate and improve veterans socials to help older veterans with depression by adapting materials, interviewing vs attendees, and collecting questionnaires. the goal is to improve the program based on the results for future use and research.

voices veterans socials is a peer-led weekly social group based in the community designed to promote sustainable social support among veterans. the research seeks to adapt and conduct a preliminary evaluation of the veterans socials (vs) intervention with older veterans. the study will develop a training procedure for vs facilitators and evaluate an open trial of this intervention. this study will determine whether a larger-scale, more definitive vs study is indicated phase 1: 13 total participants will engage in semi-structured interviews about barriers to social engagement, challenges around community-based activities, social support acquisition, and how their age and veteran status intersects with these constructs. phase 2: 20 participants will be recruited for voices veterans socials (vs) which will be conducted in 2-4 community-based social groups, with 5-10 participants in each social group. the investigators will conduct data collection on three occasions; at enrollment (pre; 0 months), at intervention completion (post; including semi-structured interview; 4 months) and at follow-up (7 months). vs procedures. twenty veterans aged 65 or older with depression will engage in vs. veterans will receive 90-minutes of weekly social engagement in a community-setting in accordance with the vs manual. each week will focus on social connections, engagement in social activities, and reinforcing behaviors that give individuals meaning and purpose.

Eligibility criteria:
inclusion criteria: * documented depressive disorder or score of 2 or more on the patient health questionnaire-2 (phq-2) * capacity to consent as determined by the university of california, san diego brief assessment of capacity to consent (ubacc) * score of 1 or more on question 3 of the ucla-3 or score of 3 or less on question 4 of the lubben social network scale 6 (lsns-6) exclusion criteria: * dsm-5 diagnosis of schizophrenia spectrum disorder or bipolar disorder * symptoms of psychosis that would interfere with study participation * probable dementia as determined by the 6-item cognitive impairment screener * suicidal ideation with plan or intent * non-english speaking * active substance use disorder (dsm-5) (within 30 days of study entry)

Keywords: veteran depression loneliness isolation veteran socials community socialization older adults
pmcf study protocol for profemur® gladiator plasma femoral stems and procotyl® l beaded acetabular components

Conditions: Joint Disease

Summary: microport orthopedics (mpo) is conducting this post market clinical follow-up (pmcf) study to evaluate the safety and efficacy of its total hip arthroplasty (tha) components marketed in the european union (eu). these types of studies are required by regulatory authorities for all tha devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the eu. this study has been designed in accordance with the medial device directives (meddev) 2.12/2 rev 2.


Eligibility criteria:
inclusion criteria: * has undergone primary tha for any of the following: * non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; * inflammatory degenerative joint disease such as rheumatoid arthritis; or * correction of functional deformity * subject is implanted with the specified combination of components * subject is willing and able to complete required study visits or assessments previously implanted bilateral subjects can have both thas enrolled in the study provided: * the specified combination of components were implanted in both * all other aspects of the inclusion/exclusion criteria are satisfied * enrollment does not exceed the subject count specified in the clinical trial agreement * the subject agrees to a second informed consent document specific to the second tha. exclusion criteria: * subjects implanted with a metal-on-metal articulation * subjects implanted with non-mpo or non-wright medical technology components (femoral heads, acetabular shells, acetabular liners) at the time of their primary tha in the enrolled tha * subjects skeletally immature (less than 21 years of age) at time of primary tha surgery * subjects currently enrolled in another clinical study which could affect the endpoints of this protocol * subjects unwilling to sign the informed consent document * subjects with substance abuse issues * subjects who are incarcerated or having pending incarceration

Keywords: osteoarthritis avascular necrosis ankylosis protrusio acetabuli painful hip dysplasia rheumatoid arthritis correction of functional deformity
an individualized online home-based exercise program for improving symptoms in disadvantaged gynecologic cancer survivors

Conditions: Malignant Female Reproductive System Neoplasm

Summary: this clinical trial tests an individualized online home-based exercise program in disadvantaged gynecologic cancer survivors and its impact on gut microbiome (the bacteria and microorganisms that live in the digestive system) and symptoms such as pain, fatigue, sleep disturbance, depression, and cognitive impairment. these symptoms can significantly reduce the quality of life (qol) and survival rate in this cancer population. thus, promoting physical activity among cancer survivors with low ses may help mitigate these severe symptoms. using online platforms such as zoom can help participants access an individualized exercise program that meets their specific needs to engage in physical activity and decrease their symptom burden. home-based exercise, by providing self-chosen time and location and low costs, can address some barriers to physical activity for cancer survivors with low ses. an individualized online home-based exercise program may be feasible, and may improve symptoms and quality of life in disadvantaged gynecologic cancer survivors.

primary objectives: i. to examine the feasibility and acceptability of an individualized home-based exercise program in gynecologic cancer survivors with low ses. ii. to test the effect of the program on gut microbiome and psychoneurological symptoms in gynecologic cancer survivors with low ses. outline: participants meet with a certified exercise trainer and complete a functional capacity assessment using a treadmill or 6-minute walk test. participants then complete an individualized online home-based exercise intervention via zoom consisting of progressive, moderate-intensity walking corresponding to the rate of perceived exertion (rpe) scale and receive social support over 30 minutes twice a week (biw) for 12 weeks.

Eligibility criteria:
inclusion criteria: * women aged ≥ 18 years old * previously diagnosed with gynecologic cancer (e.g., uterine, ovarian, cervical) * enrolled in medicaid (as a factor to determine a low ses) * completed cancer treatment (chemotherapy or chemoradiation) * able to read and speak english * do not meet recommended exercise levels as defined by the american college of sports medicine exclusion criteria: * history of metastatic or other primary cancer * serious mental health conditions (e.g., bipolar disorder, schizophrenia, major depression) * certain chronic diseases (e.g., muscular-skeletal diseases that limit mobility, autoimmune diseases, uncontrolled diabetes, hypertension, renal disease (creatinine \> 2.5 mg/dl) * unable to read/speak english * had surgery (including gynecologic surgery) within the past six weeks * are currently participating in a regular physical activity program (regular ≥ 3 times/week moderate-intensity exercise)
impact on opioid use of bundling medication-assisted treatment with mhealth

Conditions: Opioid Use Disorder

Summary: the primary aim of this study is to measure and explain the impact on long-term opioid use when medication-assisted treatment (mat) is bundled with an evidence-based mobile-health system (a-chess).


Eligibility criteria:
inclusion criteria: 1. are 18+ years old; 2. meet criteria for opioid use disorders of at least moderate severity (4 or 5 dsm-v criteria); 3. are currently taking medication-assisted treatment (mat) as part of their standard clinical care; 4. have no acute medical problem requiring immediate inpatient treatment; 5. have no history of psychotic disorders, though those with other co-morbid psychopathology (mood disorders, anxiety, other substance use disorders) will be eligible; 6. are willing to participate in a randomized clinical trial; 7. provide the name, verified telephone number, and address of at least 2 contacts willing to help locate the patient, if necessary, during follow-up; 8. are able to read and write in english; 9. are not pregnant; 10. are willing to share health-related data with primary care clinicians; and 11. are, at study intake, abstinent from opioids for at least 1 week and no longer than 2 months, except for medications used to treat the disorder (e.g., methadone).

Keywords: medication-assisted treatment (mat) buprenorphine methadone naltrexone
triage of patients presenting beyond 24 hours with ischemic stroke due to vertebrobasilar artery occlusion

Conditions: Stroke, Ischemic

Summary: endovascular thrombectomy (evt) for posterior circulation occlusion is generally performed within a window of less than 24 hours from the time the patient was last known well (lkw). the efficacy and safety of evt beyond the 24-hour window remain uncertain.


Eligibility criteria:
inclusion criteria: 1. age≥18 years.; 2. blockage in the vertebrobasilar artery, including the vertebral artery or basilar artery, determined using computed tomographic angiography (cta)/ magnetic resonance angiography (mra)/digital subtraction angiography (dsa); 3. vbao occurrence more than 24 hours from lkw; 4. none to mild premorbid disability defined by modified rankin scale (mrs) score ≤2; 5. informed consent before enrollment in the clinical trials. exclusion criteria: 1. neuroimaging evidence of cerebral hemorrhage on presentation; 2. lack of follow up information on outcomes at 90 days 3. serious, advanced, or terminal illness.
vascularized free fibula flap and computer-guided implant surgery

Conditions: Oral Tumor

Summary: the rehabilitation of patients affected by defects of the jaws after tumor resection is still very challenging. resection can lead to significant facial deformity, impaired oral functions such as speech, swallowing, saliva retention, and concomitant psychological problems. moreover, the loss of teeth and the alveolar and basal jawbone can lead to significant impairment of mastication. the reconstruction of such defects with autogenous bone grafts or revascularized free flaps has become a valuable means for the rehabilitation of these patients. major benefits of such procedure include an usually low morbidity of the donor site and an extensive length of the bone graft. moreover, vascularized grafts provide a good bulk of bone in which to place implants and a satisfactory contour. in fact, after reconstruction, local hard and soft tissue conditions often exclude the integration of conventional dentures because of the impairment of dental prosthetic retention by thin cutaneous tissue, the thickness of subcutaneous tissues, the absence of a perilingual and vestibular groove, and the fragility of soft tissues. in literature it has been well established the high biologic value of vascularized fibula grafts regarding the potential of implant osseointegration, which seemed to be equal to regional mandibular or maxillary bone and eventually capable to provide sufficient stabilization of prosthesis. it must be kept in mind that the final prosthetic success may be affected by some difficulties in this clinical scenario. these include the limited opening of the scar-contracted oral cavity, the huge amount of soft tissue covering the fibula, with little information about the profile of the underlying harvested bone, the need for limited bony exposure in a field that may well have been irradiated and they all may cause poor prosthetically-guided implant positioning and eventually disappointing results in dental rehabilitation, either functionally or esthetically. it can be postulated that these complications can be overcome, or at least reduced, by adopting the new methods of computed tomography (ct)-assisted implant surgery.


Eligibility criteria:
inclusion criteria: * patients with free fibula flaps for maxillary and mandibular reconstruction needing full arch or quasi full arch rehabilitation exclusion criteria: * radiation therapy * malignant tumor

Keywords: fibula flap oral implants computer-guided
intranasal insulin for posttraumatic stress disorder

Conditions: PTSD

Summary: to evaluate if intranasal insulin is effective in reducing ptsd symptoms.

the current proposal aims to study the pharmacotherapeutic effects of intranasal insulin on ptsd symptoms and inhibition of amygdala hyperactivation in subjects with ptsd.

Eligibility criteria:
inclusion criteria: * male or female, 21-65 years old * current ptsd * able to provide written informed consent exclusion criteria: * unstable medical condition, clinically determined by a physician * diabetes requiring insulin or oral hypoglycemic agents * moderate-severe traumatic brain injury * current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months * current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months * changes in doses of psychotropic medications in the past 4 weeks * initiation of individual therapy or counseling in the past 4 weeks * imminent suicidal or homicidal risk * contraindication to insulin * history of claustrophobia * presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-mri safety screening questionnaire

Keywords: intranasal insulin ptsd